SCP
RPRX icon

Sivia Capital Partners’s Royalty Pharma RPRX Stock Holding History

Sivia Capital Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$760K Buy
13,561
+6,082
+81% +$317K 0.09% 256
2026
Q1 		$359K Buy
+7,479
New +$328K 0.07% 322

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sivia Capital Partners's RPRX Position: Q2 2026 in Review

Sivia Capital Partners increased its Royalty Pharma (RPRX) stake by 81% in Q2 2026, buying an estimated $317K and bringing the position to 13,561 shares worth $760K. The position accounts for 0.09% of the portfolio, ranked #256.

Sivia Capital Partners first reported a position in RPRX in Q1 2026 and has held it in 2 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Sivia Capital Partners held 13,561 shares of Royalty Pharma worth $760K as of Q2 2026.
  • Sivia Capital Partners bought 6,082 Royalty Pharma shares in Q2 2026, an estimated $317K.
  • Royalty Pharma made up 0.09% of Sivia Capital Partners's portfolio in Q2 2026, its #256 holding.
  • Sivia Capital Partners first reported a position in Royalty Pharma in Q1 2026 and has held it in 2 quarters since.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Sivia Capital Partners's 13F filing for Q2 2026, filed 23 Jul 2026.